Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis

被引:328
作者
Lucchinetti, C. F. [1 ]
Gavrilova, R. H. [1 ]
Metz, I. [2 ]
Parisi, J. E. [3 ]
Scheithauer, B. W. [3 ]
Weigand, S. [4 ]
Thomsen, K. [4 ]
Mandrekar, J. [4 ]
Altintas, A. [5 ]
Erickson, B. J.
Koenig, F. [2 ]
Giannini, C. [3 ]
Lassmann, H. [6 ]
Linbo, L. [1 ]
Pittock, S. J. [1 ]
Brueck, W. [2 ]
机构
[1] Mayo Clin, Coll Med, Dept Neurol, Rochester, MN 55905 USA
[2] Univ Gottingen, Inst Multiple Sclerosis Res, Dept Neuropathol, Gottingen, Germany
[3] Lab Med & Pathol, Rochester, MN USA
[4] Hlth Sci Res, Rochester, MN USA
[5] Istanbul Univ, Dept Neurol, Istanbul, Turkey
[6] Med Univ Vienna, Ctr Brain Res, Vienna, Austria
关键词
tumefactive multiple sclerosis; demyelinating disease; biopsy; pathology; MRI;
D O I
10.1093/brain/awn098
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Atypical imaging features of multiple sclerosis lesions include size > 2 cm, mass effect, oedema and/or ring enhancement. This constellation is often referred to as 'tumefactive multiple sclerosis'. Previous series emphasize their unifocal and clinically isolated nature, however, evolution of these lesions is not well defined. Biopsy may be required for diagnosis. We describe clinical and radiographic features in 168 patients with biopsy confirmed CNS inflammatory demyelinating disease (IDD). Lesions were analysed on pre- and post-biopsy magnetic resonance imaging (MRI) for location, size, mass effect/oedema, enhancement, multifocality and fulfilment of Barkhof criteria. Clinical data were correlated to MRI. Female to male ratio was 1.2 : 1, median age at onset, 37 years, duration between symptom onset and biopsy, 7.1 weeks and total disease duration, 3.9 years. Clinical course prior to biopsy was a first neurological event in 61%, relapsing-remitting in 29% and progressive in 4%. Presentations were typically polysymptomatic, with motor, cognitive and sensory symptoms predominating. Aphasia, agnosia, seizures and visual field defects were observed. At follow-up, 70% developed definite multiple sclerosis, and 14% had an isolated demyelinating syndrome. Median time to second attack was 4.8 years, and median EDSS at follow-up was 3.0. Multiple lesions were present in 70% on pre- biopsy MRI, and in 83% by last MRI, with Barkhof criteria fulfilled in 46% prior to biopsy and 55% by follow-up. Only 17% of cases remained unifocal. Median largest lesion size on T2-weighted images was 4 cm ( range 0.5-12), with a discernible size of 2.1cm( range 0.5-7.5). Biopsied lesions demonstrated mass effect in 45% and oedema in 77%. A strong association was found between lesion size, and presence of mass effect and/or oedema (P < 0.001). Ring enhancement was frequent. Most tumefactive features did not correlate with gender, course or diagnosis. Although lesion size > 5 cm was associated with a slightly higher EDSS at last follow-up, long-term prognosis in patients with disease duration > 10 years was better ( EDSS 1.5) compared with a population-based multiple sclerosis cohort matched for disease duration ( EDSS 3.5; P < 0.001). Given the retrospective nature of the study, the precise reason for biopsy could not always be determined. This study underscores the diagnostically challenging nature of CNS IDDs that present with atypical clinical or radiographic features. Most have multifocal disease at onset, and develop RRMS by follow-up. Although increased awareness of this broad spectrum may obviate need for biopsy in many circumstances, an important role for diagnostic brain biopsy may be required in some cases.
引用
收藏
页码:1759 / 1775
页数:17
相关论文
共 105 条
  • [1] Al-Bunyan MA, 2000, SAUDI MED J, V21, P393
  • [2] Sentinel lesions of primary CNS lymphoma
    Alderson, L
    Fetell, MR
    Sisti, M
    Hochberg, F
    Cohen, M
    Louis, DN
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1996, 60 (01) : 102 - 105
  • [3] Acute demyelination, neuropathological diagnosis, and clinical evolution
    Annesley-Williams, D
    Farrell, MA
    Staunton, H
    Brett, FM
    [J]. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2000, 59 (06) : 477 - 489
  • [4] Absence of cerebrospinal fluid oligoclonal bands is associated with delayed disability progression in relapsing-remitting MS patients treated with interferon-β
    Annunziata, Pasquale
    Giorgio, Antonio
    De Santi, Lorenzo
    Zipoli, Valentina
    Portaccio, Emilio
    Amato, Maria Pia
    Clerici, Raffaella
    Scarpini, Elio
    Moscato, Gianluca
    Iudice, Alfonso
    Vacca, Giovanni
    Orefice, Giuseppe
    Morra, Vincenzo Brescia
    Maimone, Davide
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2006, 244 (1-2) : 97 - 102
  • [5] HEMORRHAGIC INTRACRANIAL MALIGNANT NEOPLASMS - SPIN-ECHO MR IMAGING
    ATLAS, SW
    GROSSMAN, RI
    GOMORI, JM
    HACKNEY, DB
    GOLDBERG, HI
    ZIMMERMAN, RA
    BILANIUK, LT
    [J]. RADIOLOGY, 1987, 164 (01) : 71 - 77
  • [6] Oligoclonal band number as a marker for prognosis in multiple sclerosis
    Avasarala, JR
    Cross, AH
    Trotter, JL
    [J]. ARCHIVES OF NEUROLOGY, 2001, 58 (12) : 2044 - 2045
  • [7] Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon β1a
    Barkhof, F
    Rocca, M
    Francis, G
    van Waesberghe, JHTM
    Uitdehaag, BMJ
    Hommes, OR
    Hartung, HP
    Durelli, L
    Edan, G
    Fernández, O
    Seeldrayers, P
    Sorensen, P
    Margrie, S
    Rovaris, M
    Comi, G
    Filippi, M
    [J]. ANNALS OF NEUROLOGY, 2003, 53 (06) : 718 - 724
  • [8] Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis
    Barkhof, F
    Filippi, M
    Miller, DH
    Scheltens, P
    Campi, A
    Polman, CH
    Comi, G
    Ader, HJ
    Losseff, N
    Valk, J
    [J]. BRAIN, 1997, 120 : 2059 - 2069
  • [9] Bale's concentric sclerosis - Report of two patients with magnetic resonance imaging follow-up
    Bolay, H
    Karabudak, R
    Tacal, T
    Onol, B
    Selekler, K
    Saribas, O
    [J]. JOURNAL OF NEUROIMAGING, 1996, 6 (02) : 98 - 103
  • [10] Non-MS recurrent demyelinating diseases
    Brinar, VV
    [J]. CLINICAL NEUROLOGY AND NEUROSURGERY, 2004, 106 (03) : 197 - 210